Disease · MONDO_0005487
Comparisons in its trials36
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 36
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Lurasidone vs Risperidone: Number of Participants With Adverse Events. | 395 of 427 | 189 of 202 | 629 | NCT00641745 | Trial comparisons |
| Lurasidone vs Risperidone: serious adverse events | 46 of 419 | 20 of 202 | 621 | NCT00641745 | Trial comparisons |
| Injectable Risperidone vs Oral Antipsychotic: serious adverse events | 96 of 187 | 91 of 182 | 369 | NCT00132314 | Trial comparisons |
| Paliperidone Extended-Release (ER) vs Placebo: serious adverse events | 11 of 214 | 8 of 95 | 309 | NCT00412373 | Trial comparisons |
| Paliperidone Extended-Release (ER) vs Placebo: Participants With Response | 85 of 211 | 26 of 93 | 304 | NCT00412373 | Trial comparisons |
| Seroquel XR vs Risperidone: serious adverse events | 4 of 109 | 4 of 107 | 216 | NCT00640562 | Trial comparisons |
| Seroquel XR vs Risperidone: Concomitant Use of Antidepressive Drugs From Baseline to Week 12 | 14 of 107 | 17 of 103 | 210 | NCT00640562 | Trial comparisons |
| Seroquel XR vs Risperidone: Concomitant Use of Antidepressive Drugs From Baseline to Week 12 | 12 of 107 | 11 of 103 | 210 | NCT00640562 | Trial comparisons |
| Varenicline vs Placebo: Number of Participants With 7-day Point Prevalence of Non-smoking at Week 12 | 16 of 84 | 2 of 43 | 127 | NCT00644969 | Trial comparisons |
| Varenicline vs Placebo: Number of Participants With 7-day Point Prevalence of Non-smoking at Week 24 | 10 of 84 | 1 of 43 | 127 | NCT00644969 | Trial comparisons |
| Varenicline vs Placebo: serious adverse events | 5 of 84 | 4 of 43 | 127 | NCT00644969 | Trial comparisons |
| Varenicline vs Placebo: Number of Participants With Suicidal Behavior and / or Ideation (Yes Response) on the Columbia Suicide Severity Rating Scale (C-SSRS) During the Treatment Phase | 9 of 82 | 4 of 43 | 125 | NCT00644969 | Trial comparisons |
| Cognitive Remediation vs Cognitive Activity Control Group: serious adverse events | 5 of 56 | 7 of 64 | 120 | NCT01173874 | Trial comparisons |
| Varenicline vs Placebo: Number of Participants With Suicidal Behavior or Suicical Ideation (Yes Response ) on the Columbia Suicide-Severity Rating Scale (C-SSRS) During the Post Treatment Phase | 6 of 70 | 0 of 39 | 109 | NCT00644969 | Trial comparisons |
| Arm 1: Pregnenolone vs Arm 2: Placebo: serious adverse events | 3 of 42 | 4 of 46 | 88 | NCT00728728 | Trial comparisons |
| CBSST + Oxytocin vs CBSST + Placebo: serious adverse events | 1 of 31 | 0 of 31 | 62 | NCT01752712 | Trial comparisons |
| Levetiracetam vs Placebo: deaths from any cause | 0 of 30 | 0 of 27 | 57 | NCT03034356 | Trial comparisons |
| Levetiracetam vs Placebo: serious adverse events | 0 of 30 | 0 of 27 | 57 | NCT03034356 | Trial comparisons |
| Omega-3 Fatty Acid vs Placebo: serious adverse events | 0 of 28 | 0 of 24 | 52 | NCT00167310 | Trial comparisons |
| Fingolimod vs Placebo: deaths from any cause | 0 of 18 | 0 of 22 | 40 | NCT01779700 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005487/comparisons